555 related articles for article (PubMed ID: 18000790)
1. The role of tissue factor pathway inhibitor in tumor growth and metastasis.
Amirkhosravi A; Meyer T; Amaya M; Davila M; Mousa SA; Robson T; Francis JL
Semin Thromb Hemost; 2007 Oct; 33(7):643-52. PubMed ID: 18000790
[TBL] [Abstract][Full Text] [Related]
2. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma.
Amirkhosravi A; Meyer T; Chang JY; Amaya M; Siddiqui F; Desai H; Francis JL
Thromb Haemost; 2002 Jun; 87(6):930-6. PubMed ID: 12083498
[TBL] [Abstract][Full Text] [Related]
3. Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Hembrough TA; Swartz GM; Papathanassiu A; Vlasuk GP; Rote WE; Green SJ; Pribluda VS
Cancer Res; 2003 Jun; 63(11):2997-3000. PubMed ID: 12782609
[TBL] [Abstract][Full Text] [Related]
4. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression.
Rak J; Klement P; Yu J
Vnitr Lek; 2006 Mar; 52 Suppl 1():135-8. PubMed ID: 16637463
[TBL] [Abstract][Full Text] [Related]
5. The role of tissue factor pathway inhibitor-2 in cancer biology.
Sierko E; Wojtukiewicz MZ; Kisiel W
Semin Thromb Hemost; 2007 Oct; 33(7):653-9. PubMed ID: 18000791
[TBL] [Abstract][Full Text] [Related]
6. Structure and biology of tissue factor pathway inhibitor.
Bajaj MS; Birktoft JJ; Steer SA; Bajaj SP
Thromb Haemost; 2001 Oct; 86(4):959-72. PubMed ID: 11686353
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor and fibrin in tumor angiogenesis.
Fernandez PM; Patierno SR; Rickles FR
Semin Thromb Hemost; 2004 Feb; 30(1):31-44. PubMed ID: 15034796
[TBL] [Abstract][Full Text] [Related]
8. Heparanase procoagulant effects and inhibition by heparins.
Nadir Y; Brenner B
Thromb Res; 2010 Apr; 125 Suppl 2():S72-6. PubMed ID: 20434010
[TBL] [Abstract][Full Text] [Related]
9. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
10. Effect of antihemostatic agents on experimental tumor dissemination.
Francis JL; Amirkhosravi A
Semin Thromb Hemost; 2002 Feb; 28(1):29-38. PubMed ID: 11885023
[TBL] [Abstract][Full Text] [Related]
11. [The role of tissue factor and its inhibitor in hemostasis].
Naumnik B; Małyszko J; Myśliwiec M
Przegl Lek; 1998; 55(2):68-73. PubMed ID: 9695646
[TBL] [Abstract][Full Text] [Related]
12. Heparanase, tissue factor, and cancer.
Nadir Y; Vlodavsky I; Brenner B
Semin Thromb Hemost; 2008 Mar; 34(2):187-94. PubMed ID: 18645924
[TBL] [Abstract][Full Text] [Related]
13. The present status of tissue factor pathway inhibitor.
Lindahl AK; Sandset PM; Abildgaard U
Blood Coagul Fibrinolysis; 1992 Aug; 3(4):439-49. PubMed ID: 1420819
[TBL] [Abstract][Full Text] [Related]
14. Heparanase coagulation and cancer progression.
Nadir Y; Brenner B
Best Pract Res Clin Haematol; 2009 Mar; 22(1):85-92. PubMed ID: 19285275
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy.
Rak J; Milsom C; May L; Klement P; Yu J
Semin Thromb Hemost; 2006 Feb; 32(1):54-70. PubMed ID: 16479463
[TBL] [Abstract][Full Text] [Related]
16. Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Nagase H; Enjyoji K; Kamikubo Y; Kitazato KT; Kitazato K; Saito H; Kato H
Thromb Haemost; 1997 Aug; 78(2):864-70. PubMed ID: 9268186
[TBL] [Abstract][Full Text] [Related]
17. [Tissue factor pathway inhibitors].
Sierko E; Zawadzki RJ; Wojtukiewicz MZ
Pol Merkur Lekarski; 2002 Jul; 13(73):66-9. PubMed ID: 12362512
[TBL] [Abstract][Full Text] [Related]
18. Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Lwaleed BA; Bass PS
J Pathol; 2006 Feb; 208(3):327-39. PubMed ID: 16261634
[TBL] [Abstract][Full Text] [Related]
19. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor in human endothelial cells in vitro.
Westmuckett AD; Kakkar VV; Hamuro T; Lupu F; Lupu C
Thromb Haemost; 2001 Dec; 86(6):1547-54. PubMed ID: 11776326
[TBL] [Abstract][Full Text] [Related]
20. Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma vasculogenic mimicry.
Ruf W; Seftor EA; Petrovan RJ; Weiss RM; Gruman LM; Margaryan NV; Seftor RE; Miyagi Y; Hendrix MJ
Cancer Res; 2003 Sep; 63(17):5381-9. PubMed ID: 14500372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
